EUVIMEDEUVIMED entdecken
Multizentrische Studie

Olverembatinib-based therapy in patients with transformed chronic myeloid leukemia in lymphoid blast phase or relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: A multicenter retrospective study

Mei Bao, Jian Huang, Zongru Li, Chunyan Chen, Linhua Yang, Yanping Ma, Yanli Zhang, Li Meng, Zhenfang Liu, Qin Wen, Suning Chen, Xiaofei Yang und 4 weitere

Clinical Lymphoma Myeloma and Leukemia · 2026

DOI: 10.1016/j.clml.2026.02.005 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026. Verfasst von Mei Bao und 15 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University Peopl…. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Antineoplastic Combined Chemotherapy Protocols, Blast Crisis. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Peking University People's Hospital, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveAntineoplastic Combined Chemotherapy ProtocolsBlast CrisisHumansFemaleMiddle AgedMaleRetrospective StudiesAdultTreatment OutcomePhiladelphia Chromosome

Stichwörter der Autor:innen

Cardiovascular eventsEfficacySafetyTyrosine kinase inhibitor

Autor:innen und Institutionen

  • National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, Chin…
  • Department of Hematology, First Affiliated Hospital of Zhejiang University, College of Medicine, Zhejiang University, Zhejiang, China.
  • Department of Hematology, Qilu Hospital of Shandong University, Jinan, China.
  • Department of Hematology, Second Hospital of Shanxi Medical University, Taiyuan, China.
  • Department of Hematology, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Henan, China.
  • Department of Hematology, Tongji Hospital of Tongji Medical College, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.

Förderung

  • Peking University People's Hospital
  • National Natural Science Foundation of China

Zitieren

APA

Bao, M., Huang, J., Li, Z., Chen, C., Yang, L., Ma, Y., Zhang, Y., Meng, L., Liu, Z., Wen, Q., Chen, S., Yang, X., Yi, H., Lin, C., Song, Y., & Jiang, Q. (2026). Olverembatinib-based therapy in patients with transformed chronic myeloid leukemia in lymphoid blast phase or relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: A multicenter retrospective study. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.02.005

Vancouver

Bao M, Huang J, Li Z, Chen C, Yang L, Ma Y, et al. Olverembatinib-based therapy in patients with transformed chronic myeloid leukemia in lymphoid blast phase or relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: A multicenter retrospective study. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2026.02.005

BibTeX
@article{Bao2026,
  author = {Bao, Mei and Huang, Jian and Li, Zongru and Chen, Chunyan and Yang, Linhua and Ma, Yanping and Zhang, Yanli and Meng, Li and Liu, Zhenfang and Wen, Qin and Chen, Suning and Yang, Xiaofei and Yi, Hai and Lin, Congmeng and Song, Yang and Jiang, Qian},
  title = {Olverembatinib-based therapy in patients with transformed chronic myeloid leukemia in lymphoid blast phase or relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: A multicenter retrospective study},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  doi = {10.1016/j.clml.2026.02.005}
}
Kostenlos starten →